Abstract Number: 1118 • ACR Convergence 2023
The Nomenclature of Calcium Pyrophosphate Deposition (CPPD) Disease – Results of a Systematic Literature Review for the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) CPPD Nomenclature Project
Background/Purpose: Despite prior attempts at standardising terminology of calcium pyrophosphate deposition (CPPD) disease (including the 2011 EULAR recommendations for CPPD terminology and diagnosis), many different…Abstract Number: 1121 • ACR Convergence 2023
Cardiovascular Safety of Febuxostat in Patients with Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials
Background/Purpose: To this date, a causal relationship between febuxostat and cardiovascular disease remains controversial as comparison between trials can be challenging and may lead to…Abstract Number: 1900 • ACR Convergence 2022
CoLchicine for Treatment of OsteoArthritis of the Knee (CLOAK)-A Double-blind, Placebo-controlled Trial
Background/Purpose: Knee osteoarthritis (OA) is an inflammatory disease, with a probable role for IL-1b. Calcium and urate crystals may promote OA by activating the NLRP3…Abstract Number: 2208 • ACR Convergence 2022
Diagnostic Performance of Hip Ultrasound in Calcium Pyrophosphate Deposition Disease
Background/Purpose: Calcium Pyrophosphate Deposition Disease (CPPD) is a chronic and potentially incapacitating disease. The reference standard for its diagnosis is the identification of calcium pyrophosphate…Abstract Number: 1145 • ACR Convergence 2022
The Prostate Plays a Role in Serum Urate Levels and the Risk of Gout in Men
Background/Purpose: Men have higher serum urate (SU) and increased prevalence of gout compared to pre-menopausal women. Xanthine oxidoreductase (XOR), encoded by the XDH gene, is…Abstract Number: 1791 • ACR Convergence 2022
Point-of-Care Multi-Energy Photon-Counting CT for Earlier Non-Invasive Diagnosis of Gout and Calcium Pyrophosphate Deposition Disease
Background/Purpose: While the definitive diagnosis of gout and calcium pyrophosphate deposition disease (CPPD) is still based on the identification of characteristic crystals in synovial fluid…Abstract Number: 1801 • ACR Convergence 2022
High Frequency of Structural Damage in the Lower Spine of Patients with Chondrocalcinosis
Background/Purpose: Calcium pyrophosphate dihydrate crystal deposition disease (CPPD, chondrocalcinosis) is known to affect fibrocartilaginous tissue in the large and smaller peripheral joints. The affection of…Abstract Number: 1804 • ACR Convergence 2022
Raman Spectroscopy Integrated with Polarized Light Microscopy for Diagnosis of Crystallopathies
Background/Purpose: The current golden standard in diagnosing gout and calcium pyrophosphate deposition is polarized light microscopy (PLM). However, small crystal sizes, the presence of other…Abstract Number: 1813 • ACR Convergence 2022
Patient-Reported Outcomes in CPPD Compared to Gout and Osteoarthritis
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease prevalence is similar to gout and osteoarthritis (OA), yet CPPD outcomes research greatly lags behind these other forms of…Abstract Number: 1817 • ACR Convergence 2022
Acute Coronary Syndrome in Calcium Pyrophosphate Deposition Disease Patients: A Cross-sectional Study from the National Inpatient Sample
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a common crystal-induced arthritis characterized by the deposition of calcium pyrophosphate crystals in the articular tissues. Acute CPP…Abstract Number: 1825 • ACR Convergence 2022
Vascular Calcifications Adjacent to the Involved Joint of Patients Diagnosed with Calcium Pyrophosphate Crystal Arthritis – a Retrospective Observational Study
Background/Purpose: Prior studies have shown an association between chondrocalcinosis (CC) and vascular calcifications. In this study, we aimed to assess the presence of vascular calcifications…Abstract Number: 0666 • ACR Convergence 2021
Process Mapping Gout Hospitalizations: A Deep Dive into an Avoidable Epidemic
Background/Purpose: Hospital admissions for gout flares have increased dramatically in recent years. Strategies to reduce hospitalizations and improve uptake of urate-lowering therapy (ULT) are needed.…Abstract Number: 0667 • ACR Convergence 2021
Active Screening for Gout Permits Identifying a Larger Cardiovascular Population at High Mortality Risk
Background/Purpose: We have recently noted by active screening that about a third of gout cases in the cardiovascular population is not registered in records (Calabuig,…Abstract Number: 0679 • ACR Convergence 2021
Cardiovascular Risk Associated with Treatment of Allopurinol and Benzbromarone in Patients with Gout
Background/Purpose: Previous studies have shown that cardiovascular risk is increased in patients with gout. There are many studies on the effect of uric acid lowering…Abstract Number: 1095 • ACR Convergence 2021
Improved Arthrocentesis and Fluid Yield of the Non-Effusive Knee Using Pneumatic Compression
Background/Purpose: Arthrocentesis is critical for diagnosis and therapy of joint disease; however, it is very difficult to obtain diagnostic fluid from an arthritic but clinically…
ACR Meeting Abstracts